Medical News

RSS

Hutchinson Technology commences tender/exchange offer of 3.25% Convertible Subordinated Notes

Hutchinson Technology Incorporated today announced that it has commenced an offer to exchange or purchase, at the election of each holder and subject to the limitations described below, up to $75,294,000 of its 3.25% Convertible Subordinated Notes due 2026 (the "Old Notes").

10 Jan 2011

DATATRAK awarded Phase III device study by new European client

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced that it has been awarded a Phase III device study by a new European client, a leading global healthcare supplier.

10 Jan 2011

SonoSite fourth quarter revenue increases 27% to $89 million

SonoSite, Inc., the world leader and specialist in bedside and point-of-care ultrasound, today announced preliminary revenue results for the fourth quarter and year ended December 31, 2010.

10 Jan 2011

Adolor initiates second ADL5945 Phase 2 study in opioid-induced constipation

Adolor Corporation today announced that it is initiating a second Phase 2 study of ADL5945 in chronic non-cancer pain patients suffering from opioid-induced constipation (OIC).

10 Jan 2011

Emergent BioSolutions estimates total revenue of $285 to $288 million for 2010

Emergent BioSolutions Inc. announced today preliminary, unaudited financial results for 2010 and guidance for 2011.

10 Jan 2011

Align and Cadent enter joint software development agreement for Invisalign treatment

Align Technology, Inc. and Cadent, Inc., today announced an agreement to jointly develop software applications that will run on Cadent iTero and iOC scanners for use in Invisalign treatment. The new applications will optimize case assessment and planning for Invisalign treatment, and bring valuable digital tools chair-side for Invisalign providers who use Cadent scanners.

10 Jan 2011

Sangamo completes enrollment in SB-509-901 Phase 2b clinical trial in diabetic neuropathy

Sangamo BioSciences, Inc. announced today that the company completed enrollment of its Phase 2b double-blind, placebo-controlled clinical trial (SB-509-901) in subjects with diabetic neuropathy (DN). The company expects to have efficacy data from this study in the second half of 2011. The company also plans to present the first human clinical data from its Phase 1 trials of SB-728-T in HIV/AIDS in the first quarter of 2011.

10 Jan 2011

Pennsaid fourth quarter prescriptions increase 20% sequentially

Nuvo Research Inc., a specialty pharmaceutical company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced it will be meeting with several U.S. investment bankers, analysts and fund managers during J.P. Morgan's 29th annual Healthcare Conference held from January 10th to January 13th, 2011, in San Francisco, California.

10 Jan 2011

New, paid prescriptions for Questcor's Acthar increase 66%

Questcor Pharmaceuticals, Inc. today reported a strong finish to 2010. The Company estimates that 353 new, paid Acthar prescriptions for the treatment of multiple sclerosis (MS) were filled and shipped during the quarter, up 66% from the year ago period and up 9% from the third quarter of 2010.

10 Jan 2011

Enzon to commence EZN-4176 Phase 1a/1b study in castration-resistant prostate cancer

Enzon Pharmaceuticals, Inc. today announced the Investigational New Drug (IND) approval by the US Food and Drug Administration (FDA) and plan to commence enrollment into a Phase 1a/1b study shortly. The study will evaluate the safety and tolerability of EZN-4176, the company's novel androgen receptor (AR) mRNA antagonist, for the treatment of patients with castration-resistant prostate cancer (CRPC).

10 Jan 2011

Watson receives FDA approval for generic Fentora

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for Fentanyl Buccal tablets, USP, in the 0.1, 0.2, 0.4, 0.6 and 0.8 mg strengths, the generic equivalent to Cephalon's Fentora ® tablets.

10 Jan 2011

Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study

Oncolytics Biotech Inc. announced today that a U.S. Phase I study of REOLYSIN® in combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer (REO 022) is now open to enrollment. The principal investigator is Dr. Sanjay Goel of the Montefiore Medical Center at The Albert Einstein College of Medicine in New York.

10 Jan 2011

Civitas receives $20 million Series A financing

Civitas Therapeutics, Inc., a privately held biopharmaceutical company focused on developing transformative pulmonary delivery therapies, announced today that it has secured a $20 million Series A financing from founding investor, Longitude Capital, along with co-lead Canaan Partners. The proceeds of the financing will be primarily used to advance Civitas' lead program for treating patients with Parkinson's disease through clinical proof-of-concept.

10 Jan 2011

Omega-3 fatty acid may help protect against traumatic brain injury

Animal experiments suggest that taking the omega-3 fatty acid docosahexanoic acid (DHA) might offer a new way of protecting against traumatic brain injury (TBI), reports the February issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

10 Jan 2011

95.6% of WTC survivors report posttraumatic stress symptoms

Nearly 10 years after the greatest human-made disaster in U.S. history-- the destruction of the World Trade Center (WTC) towers -- there has been little research documenting the attacks' consequences among those most directly affected -- the survivors who escaped the World Trade Center towers.

10 Jan 2011

Bioheart reports positive data from adipose derived stem cells study in critical limb ischemia

Bioheart, Inc. announced positive efficacy data has been reported from the registry study of bone marrow and adipose derived stem cells for the treatment of end stage critical limb ischemia with wounds. Vaclav Prochazka MD, PhD, MSc., of University Hospital Ostrava, Czech Republic presented data at the American Academy of Anti-Aging Medicine Conference in Las Vegas last month.

10 Jan 2011

Research suggests novel therapeutic approach for Huntington's Disease

Hope for new ways of treating devastating neurodegenerative disorders such as Huntington's disease has been raised by a trans-Atlantic team of researchers thanks to the use of cutting-edge genetic techniques.

10 Jan 2011

DGT Holdings completes reverse/forward stock split

DGT Holdings Corp. announced today that it has completed the previously announced reverse stock split at a ratio of one-for-fifty and a forward stock split at a ratio of four-for-one. All shareholders owning fewer than fifty shares and all fractional shares remaining following the forward stock split have been cancelled and shareholders will receive a cash payment based on the ten day average closing price of the common stock prior to the splits.

10 Jan 2011

Key Equipment Finance and Hitachi Medical Systems America enter new partnership

Key Equipment Finance, one of the nation's largest bank-held equipment finance companies and an affiliate of KeyCorp today announced that the company has entered into an exclusive, long term, program agreement with Hitachi Medical Systems America. Hitachi Medical Systems America is the U.S. distributor of Hitachi Medical Corporation's diagnostic imaging products.

10 Jan 2011

Takeda San Francisco and Pieris enter Anticalin scaffold technology collaboration

Takeda San Francisco (TSF) and Pieris AG have signed a drug discovery partnership agreement under which Pieris will apply its Anticalin(R) scaffold technology to deliver protein therapeutic candidates to Takeda, both companies announced today. The deal initially will focus on first-in-class drug discovery efforts around a predetermined Takeda target.

10 Jan 2011

Medical News

Hutchinson Technology commences tender/exchange offer of 3.25% Convertible Subordinated Notes

DATATRAK awarded Phase III device study by new European client

SonoSite fourth quarter revenue increases 27% to $89 million

Adolor initiates second ADL5945 Phase 2 study in opioid-induced constipation

Emergent BioSolutions estimates total revenue of $285 to $288 million for 2010

Align and Cadent enter joint software development agreement for Invisalign treatment

Sangamo completes enrollment in SB-509-901 Phase 2b clinical trial in diabetic neuropathy

Pennsaid fourth quarter prescriptions increase 20% sequentially

New, paid prescriptions for Questcor's Acthar increase 66%

Enzon to commence EZN-4176 Phase 1a/1b study in castration-resistant prostate cancer

Watson receives FDA approval for generic Fentora

Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study

Civitas receives $20 million Series A financing

Omega-3 fatty acid may help protect against traumatic brain injury

95.6% of WTC survivors report posttraumatic stress symptoms

Bioheart reports positive data from adipose derived stem cells study in critical limb ischemia

Research suggests novel therapeutic approach for Huntington's Disease

DGT Holdings completes reverse/forward stock split

Key Equipment Finance and Hitachi Medical Systems America enter new partnership

Takeda San Francisco and Pieris enter Anticalin scaffold technology collaboration

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News